Coronavirus Pipeline: GSK And Clover Add To Collaborations
Pipeline Review – Update On Companies Joining Research
Companies continue to throw their hats into the ring against the virus, with strategies ranging from ‘off the shelf’ molecules to novel vaccine and anti-viral therapies
You may also be interested in...
The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
The coronavirus outbreak is at a tipping point, after which its development into a global pandemic may be unstoppable. Companies large and small have mobilized in the fight against the disease bringing new and repurposed treatment options into development and preparing their business for the unsteady months ahead.